Compound class:
Synthetic organic
Comment: Compound 24 is one of the clinical lead C-C motif chemokine receptor 9 (CCR9) antagonists reported in [2]. It is also one of the compounds claimed in patent WO2015097121 [1]. CCR9 modulators (e.g. antagonists, partial agonists or inverse agonists) are of clinical interest for their potential to treat, prevent or ameliorate condtions such as inflammatory bowel disease (IBD), in which CCR9 activation is believed to be associated with the pathology. Compound 24 exhibits an improved pharmacokinetic (PK) profile compared to the prototype CCR9 antagonist vercirnon.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Immunopharmacology Disease | |||
Disease | X-Refs | Comment | References |
Colitis | Experimental compound with predicted application in inflammatory bowel disease. |